The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy

Negredo, Eugèniaa; Clotet, Bonaventuraa,b; Puig, Jordia; Pérez-Álvarez, Núriaa; Ruiz, Lidiab; Romeu, Joana; Moltó, Joséa; Rey-Joly, Celestinoc; Blanco, Juliàb

doi: 10.1097/01.aids.0000210617.90954.0e
Research Letters

We conducted a pilot study to assess the effect of atorvastatin on HIV replication. Patients with stable HAART-controlled infection interrupted therapy and were randomly assigned to a control group or to start atorvastatin 40 or 80 mg/day. Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4.

aLluita contra la SIDA

bIrsicaixa Foundations

cInternal Medicine Department, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.

Received 7 October, 2005

Accepted 19 October, 2005

Sponsorship: This work was partly supported by the Spanish Fondo de Investigación Sanitaria (FIS), project 02/0879 and Red Temática Cooperativa de Investigacion en SIDA (RIS). J. Blanco is a researcher from Fundació de Recerca Germans Trias i Pujol.

© 2006 Lippincott Williams & Wilkins, Inc.